## MTD: Mettler-Toledo International Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.5% below STRENGTH zone (3.0-6.0%); PEG 5.80 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.3% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($1349.09)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Texas Permanent School Fund Corp Cuts Stock Position in Mettler-Toledo International, Inc. $MTD**
- Source: MarketBeat | 20251223T103925 | Somewhat-Bearish | Relevance: 100%
- Texas Permanent School Fund Corp reduced its stake in Mettler-Toledo International by 42.4% in Q2, selling 1,077 shares and holding 1,463 shares valued at approximately $1.72 million. Despite this reduction, other major institutions like Bank of New York Mellon and Norges Bank significantly increased or initiated positions, leading to institutional investors owning about 95.07% of the company. Mettler-Toledo beat recent EPS estimates and provided strong FY2025 guidance, but analyst consensus remains a "Hold" with a $1,441.67 target, while insiders have sold a substantial amount of shares.

**2. Seilern Investment Management Ltd Sells 4,623 Shares of Mettler-Toledo International, Inc. $MTD**
- Source: MarketBeat | 20251222T110914 | Somewhat-Bullish | Relevance: 100%
- Seilern Investment Management Ltd reduced its stake in Mettler-Toledo International, Inc. by 7.2%, selling 4,623 shares and now holding 59,665 shares valued at approximately $73.25 million. This reduction comes amid recent insider selling activity, although the medical instruments supplier reported strong quarterly earnings, beating analyst expectations for both EPS and revenue. Mettler-Toledo also provided optimistic FY2025 guidance.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Barclays | $1550 | $1600 | -3% |
| 2025-12-15 | Wells Fargo | $1450 | $1400 | +4% |
| 2025-12-09 | Goldman Sachs | $1475 | $0 | 0% |
| 2025-12-02 | Morgan Stanley | $1550 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Barclays | main | Overweight |
| 2025-12-15 | Wells Fargo | main | Equal-Weight |
| 2025-12-09 | Goldman Sachs | init | Neutral |
| 2025-12-02 | Morgan Stanley | init | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 18 ($1.28M) |
| Sells | 6 ($0.98M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 50.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.7% (+1.4%)
- Blackrock Inc.: 9.2% (-3.1%)
- State Street Corpora: 4.7% (-0.5%)
- Capital Internationa: 4.2% (+1.2%)
- Bank Of New York Mel: 4.0% (-9.0%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-2.3% 5d) with bearish MACD, trend may be turning.
2. Valuation stretched: PEG 5.8x requires aggressive growth execution.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 5.80 signals overvaluation risk, limited margin of safety. Forward P/E 30.9x stretched relative to 8% growth. Quality metrics strong (ROE 30%, ROA 20%, margin 21%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $29.1B |
| Beta | 1.40 |
| 52W Range | $946.69 - $1525.17 |
| Short Interest | 4.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 5.80 |
| Forward P/E | 30.9 |
| Current P/E | 33.5 |
| YoY Growth | 8.4% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 1.8% to -0.5% (-2.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.5pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.13x) but short-term weakness (below SMA20). MACD histogram bearish (-1.89), momentum weakening. RSI neutral at 51. OFD pattern: +MTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.49% (CS: 59) | Neutral |
| RSI_14 | 51.0 | Neutral |
| MACD Histogram | -1.89 | Bearish |
| vs SMA20 | 0.994x | Below |
| vs SMA50 | 1.002x | Above |
| vs SMA200 | 1.131x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $1413.59
- **Stop Loss:** $1349.09 (4.6% risk)
- **Target:** $1478.09 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 18
- **Position Value:** $25,444.62
- **Portfolio %:** 25.44%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-02-05 (Est: $12.80)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $10.66 | $11.15 | +4.6% |
| 2025Q2 | $9.60 | $10.09 | +5.1% |
| 2025Q1 | $7.88 | $8.19 | +3.9% |
| 2024Q4 | $11.72 | $12.41 | +5.8% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*